-=Prothena (PRTA) : discontinues development of NEOD001

Prothena to discontinue development of NEOD001 based on results from the Phase 2b PRONTO study and a futility analysis of the Phase 3 VITAL study  
Based on the results from the Phase 2b PRONTO study, which did not meet its primary or secondary endpoints, the Company asked the independent data monitoring committee (DMC) of the Phase 3 VITAL study to review a futility analysis of the ongoing VITAL study. The DMC recommended discontinuation of the VITAL study for futility. The Company therefore decided to discontinue all development of NEOD001, including the VITAL study as well as the open label extension studies.